MED: the cash flow

MyFinsight

For the year ending 2025-12-31, MED had -$1,625K decrease in cash & cash equivalents over the period. $1,249K in free cash flow.

Cash Flow	2025-12-31
Revenue	385,788
Cost of sales	110,601
Selling, marketing, and after sales support	187,986
Distribution	17,767
Technology	43,744
Administrative and corporate support functions	32,264
Equity compensation	7,639
Other income	8,574
Provision for income taxes	13,033
Net income (loss)	-18,672
Depreciation and amortization	14,242
Non-cash lease expense	4,624
Share-based compensation	7,639
Loss on sale of disposal of property, plant and equipment	-1,373
Realized gain on sale of investment securities	3,310
Amortization of discount on investment securities	671
Deferred income taxes	11,460
Unrealized (gain) loss on equity investment securities	17
Non-cash charges for supply chain optimization	0
Inventories	-22,193
Income taxes	-6,601
Prepaid expenses and other current assets	-573
Other assets	2,057
Accounts payable and accrued expenses	-23,913
Net cash flow provided by operating activities	6,863
Purchase of investment securities	84,407
Proceeds from sale and maturities of investment securities	82,093
Purchase of property and equipment	5,614
Net cash flow used in investing activities	-7,928
Options exercised by executives and directors	0
Net shares repurchased for employee taxes	369
Cash dividends paid to stockholders	195
Stock repurchases	0
Net cash flow used in financing activities	-564
Foreign currency impact	4
Increase (decrease) in cash and cash equivalents	-1,625
Cash and cash equivalents at beginning of period	90,928
Cash and cash equivalents at end of period	89,303

Unit: Thousand (K) dollars (except for numbers of shares and EPS).